comprehensive -WSS

comprehensive

author：leisure time 2025-10-01 12:34:42 - browse：75246

There are a lot of reasons why updated data on Pfizer’s Lorbrena, a treatment for non-small cell lung cancer, might not seem to be a big deal. The results are an update on the clinical trial that resulted in the Food and Drug Administration granting Lorbrena full approval in 2001, so in a sense they are not even that new. For Pfizer investors, Lorbrena isn’t that big a deal, either. The medicine, for patients whose lung tumors have particular genetic mutations, generated only $575 million last year — an amount that is up 57% from the year prior, but that still constitutes only 1% of the drug giant’s annual sales.

But there is one number that makes the Lorbrena data quite eye-catching: In the updated data, the daily pill decreased the risk that cancer would progress or that a patient would die by 81% over five years.

That’s a stunning number, especially when one considers that Lorbrena was not being compared to an inert placebo but to Xalkori, another Pfizer targeted cancer drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： CRISPR gene editing developments we’re watching in 2024

WSS

ProMED sees offers of support, but its future remains unclear

In Spain, a hospital brews its own CAR

Majority of Americans think Trump's Ga. election interference case is serious: POLL

Evacuations in place as 3 wildfires burn in eastern Washington state

Congress must give Medicare recipients genetic counseling access

Ukraine taking heavy casualties 10 weeks into its counteroffensive

Wikipedia

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Jerome Adams on the need for new antivirals for Covid

Prime Medicine, Myeloid Therapeutics clash over genome

23andMe had bad news about my health. I wish a person had delivered it

Liz Cheney makes 1st public comment since Trump's election interference indictments

Medical leaders decry Supreme Court decision on affirmative action

Can sheer will power keep patients alive in their dying hours?

Malaria cases in Florida and Texas: Here’s what you need to know

Vaccine critic Robert F. Kennedy Jr. says he'll chair Trump vaccine panel

Cancer drug shortages should be causing more outrage

Eye stem cell transplant could help restore vision in injured people

focus

Beware the threat of staffing cuts at the CDC

Prime Medicine, Myeloid Therapeutics clash over genome

Prime Medicine, Myeloid Therapeutics clash over genome

HCA sued by state AG for quality issues at Mission Health

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Clinical trials must include more disabled people

leisure time

hotspot

Wikipedia

hotspot